An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination With An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
ID Number 11-0856Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to identify any side effects with the study drug combination when MLN9708 is given at different doses. The study is also trying to find out the effects, good and/or bad the study drug combination has on your type of cancer. This is the eighth study in which patients will been given MLN9708. It is thought that MLN9708 interferes with how multiple myeloma cells breakdown proteins. In this study, you will receive an investigational drug called MLN9708 in combination with Lenalidomide and low-dose Dexamethasone (both standard drugs).
Lenalidomide and low-dose Dexamethasone given in combination is FDA approved for the treatment of multiple myeloma patients who have received at least one prior therapy.
Recruiting Patients: Yes